M
Michael D. McGoon
Researcher at Mayo Clinic
Publications - 181
Citations - 38442
Michael D. McGoon is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pulmonary hypertension & Blood pressure. The author has an hindex of 77, co-authored 181 publications receiving 35845 citations. Previous affiliations of Michael D. McGoon include University of Alabama at Birmingham & University of Rochester.
Papers
More filters
Journal ArticleDOI
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Robyn J. Barst,Lewis J. Rubin,Walker Long,Michael D. McGoon,Stuart Rich,David B. Badesch,Bertron M. Groves,Victor F. Tapson,Robert C. Bourge,Bruce H. Brundage,Spencer K. Koerner,David Langleben,Cesar A. Keller,Srinivas Murali,Barry F. Uretsky,Linda M. Clayton,Maria M. Jöbsis,Shelmer D. Blackburn,Denise Shortino,James W. Crow +19 more
TL;DR: As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.
Journal ArticleDOI
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association
Vallerie V. McLaughlin,Stephen L. Archer,David B. Badesch,Robyn J. Barst,Harrison W. Farber,Jonathan R. Lindner,Michael A. Mathier,Michael D. McGoon,Myung H. Park,Robert S. Rosenson,Lewis J. Rubin,Victor F. Tapson,John Varga +12 more
TL;DR: In this paper, the authors discuss the role of the chairperson of FAHA and the chair's role in the FAHA Board of Trustee selection process and propose a new chairperson for FAHA.
Journal ArticleDOI
Valvular Heart Disease Associated with Fenfluramine–Phentermine
Heidi M. Connolly,Jack L. Crary,Michael D. McGoon,Donald D. Hensrud,Brooks S. Edwards,William D. Edwards,Hartzell V. Schaff +6 more
TL;DR: Concerns are raised that fenfluramine-phentermine therapy may be associated with valvular heart disease, which is arouse concern about serious potential adverse effects, including pulmonary hypertension and valvULAR heart disease.
Journal ArticleDOI
Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
Raymond L. Benza,Dave P. Miller,Mardi Gomberg-Maitland,Robert P. Frantz,Aimee J. Foreman,Christopher S. Coffey,Adaani E. Frost,Robyn J. Barst,David B. Badesch,C. Gregory Elliott,Theodore G. Liou,Michael D. McGoon +11 more
TL;DR: This work identified key predictors of survival based on the patient's most recent evaluation and formulated a contemporary prognostic equation that may allow the individualization and optimization of therapeutic strategies.
Journal ArticleDOI
Right Ventricular Function and Failure Report of a National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure
Norbert F. Voelkel,Robert A. Quaife,Leslie A. Leinwand,Robyn J. Barst,Michael D. McGoon,Daniel R. Meldrum,Jocelyn Dupuis,Carlin S. Long,Lewis J. Rubin,Frank W. Smart,Yuichiro J. Suzuki,Mark T. Gladwin,Elizabeth M. Denholm,Dorothy B. Gail +13 more
TL;DR: A working group charged with delineating in broad terms the current base of scientific and medical understanding about the right ventricle and identifying avenues of investigation likely to meaningfully advance knowledge in a clinically useful direction is convened.